This invention relates to a novel use of IL-1 .beta.-ligand/IL-1 receptordisruptingcompounds (herein referred to as "IL-1 beta Compounds")； such as smallmolecularcompounds disrupting IL-1 .beta. ligand - IL-1 receptor interaction, IL-1.beta. antibodies orIL-1 receptor antibodies, e.g. IL-1 .beta. binding molecules described herein,e.g. antibodiesdisclosed herein, e.g. IL-1 .beta. binding compounds or IL-1 receptor bindingcompounds,and/or RNA compounds decreasing either IL-1 .beta. ligands or IL-1 receptorproteinlevels, in the treatment and/or prevention of auto-inflammatory syndromes,e.g.Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and tomethodsof treating and/or preventing auto-inflammatory syndromes, e.g. Juvenilerheumatoidarthritis or adult rheumatoid arthritis syndrome, in mammals, particularlyhumans.
